# Genetic or pharmacological disruption of the MSH3 Y245/K246 IDL binding pocket slows CAG repeat expansion.

- **DOI:** [10.1093/narmme/ugag031](https://doi.org/10.1093/narmme/ugag031)
- **Rating:** Strong (3.8 out of 5)
- **Verdict:** Cellular genetic and chemical evidence validates the MSH3 IDL pocket as an expansion target, but CP1’s on-target specificity remains unresolved.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1093%2Fnarmme%2Fugag031

## Key claims

1. Genetic disruption of the MSH3 Y245/K246 motif significantly reduced DNA interaction, exhibited MMR deficiency in a frameshift mutator assay, and abrogated repeat expansion in a U2OS cell line expressing mutant HTT exon 1.
   - Support: Tentative
   - Type: Primary finding
   - Basis: “Abrogated” overstates the small but significant residual expansion reported for YSKE cells
   - Location: Abstract; Results, Fig. 1D–H
2. CP1 treatment slowed expansion at both 2.5 and 5 µM.
   - Support: Supported
   - Type: Secondary
   - Basis: dose-responsive cellular evidence, with significance reached only at 5 µM and incomplete pharmacological specificity
   - Location: Results, “A small molecule targeting the MSH3 IDL binding pocket slows CAG repeat expansion,” Fig. 5A–C
3. Crucially, this molecule also slowed CAG repeat expansion in medium spiny neurones derived from HD patient-iPSCs.
   - Support: Supported
   - Type: Secondary
   - Basis: one donor-derived enriched culture supports direction, while MSH3 lowering and off-target binding limit attribution
   - Location: Abstract; Results, Fig. 5E–H

## Strengths

- **Orthogonal genetic and biochemical evidence** The YSKE pocket mutant is evaluated alongside wild-type rescue and an ATPase-dead comparator, while ChIP, oligo pull-down, interaction assays, EMAST, and expansion time courses test distinct parts of the proposed mechanism.
  - Dimension: methodological rigour
  - Location: Results, Figs. 1–3
- **Extension into patient-derived neurons** CP1 target engagement and repeat-expansion effects are assessed during prolonged treatment of HD patient-iPSC-derived MSN-enriched cultures, extending the work beyond the U2OS model.
  - Dimension: contribution
  - Location: Results, Figs. 4E–F and 5E–H
- **Limitations inform the conclusions** The Discussion addresses reduced MSH3 abundance, PTGES2 and other off-target binding, higher-dose toxicity, and the limitations of U2OS and mixed neuronal cultures before restricting the claim to future target study.
  - Dimension: positioning
  - Location: Discussion, paragraphs 6–8

## Limitations

- **CP1 specificity remains incompletely established** The pharmacological experiments lack an inactive analogue and an epistasis test in MSH3-knockout or YSKE cells. CP1 also reduces neuronal MSH3 abundance and has acknowledged off-target binding, so pocket occupancy is not the only possible explanation.
  - Dimension: methodological rigour
  - Location: Results, Figs. 4E–F and 5; Discussion, paragraphs 6–7
- **Neuronal evidence has narrow breadth** The disease-relevant arm uses one patient-derived iPSC line and mixed cultures in which roughly one third of cells express MSN markers. This limits generalisation across donors and neuronal preparations.
  - Dimension: methodological rigour
  - Location: Methods, Human iPSC Line Maintenance and Differentiation; Results, target-engagement subsection; Supplementary Fig. S4C–D
- **Abstract overstates genetic suppression** The Abstract says the YSKE mutation “abrogated” expansion, but Results report a small significant positive slope and the Discussion describes only minimal increases. The direction of the finding remains intact, but elimination is not demonstrated.
  - Dimension: reporting
  - Location: Abstract; Results, first subsection, Fig. 1D–F; Discussion, paragraph 4

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - Genetic disruption of the MSH3 Y245/K246 motif significantly reduced DNA interaction, exhibited MMR deficiency in a frameshift mutator assay, and abrogated repeat expansion in a U2OS cell line expressing mutant HTT exon 1: "Genetic disruption of the MSH3 Y245/K246 motif significantly reduced DNA interaction, exhibited MMR deficiency in a frameshift mutator assay, and abrogated repeat expansion in a U2OS cell line expressing mutant HTT exon 1." (Abstract) vs "whereas myc MSH3 YSKE cells show a small but significant increase in repeat size (slope different from zero, P = .0141)." (Results, Generating a cell system to study MSH3 function in CAG repeat expansion). The Abstract's assertion that expansion was abrogated is contradicted by the Results' explicitly positive YSKE expansion slope, reported as significantly different from zero at P = .0141. → Not supported by the paper's own data
- **Reporting and transparency:** Noted. The EMAST reporter citation changes from [38] in Methods to [37] in Results, and eight-fold overexpression is associated with different supplementary-figure references; neither establishes a changed experimental result.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared
- **Reference integrity:** Clean
  - 42 references in manuscript
  - 42 of 42 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
